SBH
XENT

Segall Bryant & Hamill’s Intersect ENT, Inc XENT Stock Holding History

Segall Bryant & Hamill’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-16,935
Closed -$385K – 858
2019
Q2 		$385K Buy
16,935
+68
+0.4% +$1.83K 0.01% 705
2019
Q1 		$542K Buy
16,867
+417
+3% +$12.9K 0.01% 643
2018
Q4 		$464K Sell
16,450
-1,993
-11% -$58.4K 0.01% 660
2018
Q3 		$530K Sell
18,443
-57
-0.3% -$1.71K 0.01% 667
2018
Q2 		$693K Buy
+18,500
New +$726K 0.01% 609

Other funds holding XENT

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Segall Bryant & Hamill's XENT Position: Q3 2019 in Review

Segall Bryant & Hamill sold out of Intersect ENT, Inc (XENT) in Q3 2019, closing a stake of 16,935 shares — an estimated $385K sold.

Segall Bryant & Hamill first reported a position in XENT in Q2 2018 and held it in 5 quarters. The position peaked at $693K in Q2 2018. 112 funds tracked by Wall St. Rank hold XENT as of Q3 2019.

  • Segall Bryant & Hamill reported no remaining Intersect ENT, Inc position as of Q3 2019 after selling out during the quarter.
  • Segall Bryant & Hamill sold 16,935 Intersect ENT, Inc shares in Q3 2019, an estimated $385K.
  • Segall Bryant & Hamill first reported a position in Intersect ENT, Inc in Q2 2018 and held it in 5 quarters.
  • Segall Bryant & Hamill's Intersect ENT, Inc position peaked at $693K in Q2 2018.
  • 112 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q3 2019.

Based on Segall Bryant & Hamill's 13F filing for Q3 2019, filed 12 Nov 2019.